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Testicular cancer is a rare disease that affects 1-2 in 100,000 people in Japan ; however, it is a very
significant disease in that it has a high prevalence amongst young adults aged in their 20s and 30s and it
brings about metastasis from a relatively early stage. The 2009 edition of the Testicular Cancer Clinical
Practice Guidelines sets out a detailed summary of 32 clinical questions (CQ) considered necessary in routine
clinical practice across the fields of epidemiology, diagnosis, treatment, etc, in the form of recommendations
and commentary. These CQs are considered extremely important in understanding the foundation of
future testicular cancer treatment guidelines. In this symposium, five doctors gave lectures consisting of the
following contents in which they validated the guidelines and gave concrete clinical practice examples
through cases they had experienced themselves with regards to the treatment strategies for (1) stage I patients,
(2) patients with advanced cancer and (3) patients with extragonadal germ cell tumors. (1) Stage I patients :
In seminoma cases, the doctors focused on the relapse prevention effect provided by single-agent carboplatin
adjuvant chemotherapy. In non-seminoma cases, treatment options were considered according to risk
based on the presence or absence of vascular invasion, a prognostic factor. (2) Patients with advanced
cancer : 30% of testicular cancers are metastatic and progress to advanced cancer. In refractory cases
resistant to bleomycin, etoposide and cisplatin therapy, etoposide ifosfamide, and cisplatin therapy and
vinblastine, ifosfamide and cisplatin therapy have been used, but without satisfactory results and the
development of new salvage chemotherapy is an important issue. The therapeutic strategies against
advanced testicular cancer were narrowed down to (2) -1) therapeutic effects from ultra-high-dose
chemotherapy, (2) -2) salvage chemotherapy in cases where residual tumors are observed in induction
chemotherapy and (2) -3) minimally invasive surgical treatment for residual tumors after chemotherapy.
Concrete clinical cases from basic treatment strategies to the latest findings in refractory cancer patients were
presented and considered in detail. (3) Patients with extragonadal germ cell tumors : Extragonadal germ cell
tumors account for less than 5% of all germ cell tumors, but they can be cured with multimodality therapy.
Therefore, it is important to reach an accurate diagnosis and provide the correct treatment. This disease is
suspected in patients with elevated α-fetoprotein and human chorionic gonadotropin without the appearance
of tumors in the testes, and tumors can be observed on the center line of the body such as the mediastinum or
retroperitoneum. Traditionally, computed tomography-guided biopsy has been carried out in diagnosis.
However, new techniques such as endoscopic ultrasound-guided biopsy have also been reported in recent
years and the latest information, including treatments, was presented at this symposium.
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